Another 17 U.S. billionaires, including Facebook co-founders Mark Zuckerberg and Dustin Moskovitz, have pledged to give away at least half their fortunes in a philanthropic campaign led by Warren Buffett and Bill Gates.
Another 17 U.S. billionaires, including Facebook co-founders Mark Zuckerberg and Dustin Moskovitz, have pledged to give away at least half their fortunes in a philanthropic campaign led by Warren Buffett and Bill Gates.
Motorola, Inc. (MOT) said it has reduced the time frame for its plan to separate handset and cable set-top box businesses Motorola Mobility Holdings, Inc. from the company to January next year.
Energy firm Dynegy Inc said it intends to terminate the merger deal with Blackstone Group and seeks new proposals from potentially interested parties.
The top after-market NASDAQ stock market losers are: RINO International, Renasant, Anadigics, China Natural Gas, Allos Therapeutics, Sina, Avanir Pharmaceuticals, Mattel, Ariad Pharmaceuticals, and Bob Evans Farms.
Investor Carl Icahn increased his bid to buy Lions Gate Entertainment Corp on Tuesday to $7.50 per share, valuing the company at $1 billion and sending shares up more than 12 percent.
Sanofi-Aventis is doing everything possible to cajole, pressure and manipulate Genzyme Corp into entering acquisition talks based on its opening offer of $69 a share.
U.S. biotech company Genzyme Inc rejected an $18.5 billion (11.9 billion pound) buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially hostile takeover battle.
France's Sanofi-Aventis on Sunday publicly disclosed its $18.5 billion, $69-per-share cash offer for Genzyme Corp in a bid to rouse shareholders after failing to engage the U.S. biotechnology company in merger talks.
France's Sanofi-Aventis disclosed its $18.5 billion offer for Genzyme Corp in a bid to rouse shareholders after failing to engage the company in merger talks.
Billionaire investor Carl Icahn has increased his holding in Motorola Inc to about 10.4 percent, according to documents the company filed with the U.S. Securities and Exchange Commission.
Sanofi-Aventis investors have urged the drugmaker not to pay more than about $19 billion to land Genzyme, some $10 a share below the price wanted by the U.S. biotech group.
Sanofi-Aventis chief Chris Viehbacher should avoid paying much more than about $70 per share, or a total of $19 billion, to land U.S. biotech group Genzyme, shareholders in the French group say.
LOS ANGELES - The James Bond 007: Blood Stone video game event in London this month had all the class and splash one would expect from the world's most elegant spy.
Biotechnology company Genzyme Corp is weighing an informal takeover approach from France's Sanofi-Aventis but is not looking to sell the company, a source familiar with the situation said on Monday.
Billionaire Carl Icahn on Monday accused Lions Gate Entertainment Corp of using scorched-earth tactics to thwart his bid to take over the Hollywood studio and pledged legal action to stop it.
Sstock index futures pointed to a mixed open on Wall Street on Friday, with futures for the S&P 500 down 0.1 percent, Dow Jones futures down 0.12 percent and Nasdaq 100 futures up 0.03 percent at 0745 GMT.
Two initial public offerings rose in their Thursday debuts as the broader U.S. market fell.
Activist investor Carl Icahn has abandoned his proxy fight at Genzyme Corp in return for the biotechnology company's acceptance of two of his representatives to its board.
Activist investor Carl Icahn has abandoned his proxy fight at Genzyme Corp in return for the biotechnology company's acceptance of two of his representatives to its board.
Lions Gate Entertainment has spoken to billionaire investor Carl Icahn a couple of times over his hostile $7 per share offer for the company, its chief executive said on Wednesday.
Stock index futures pointed to a higher open on Wall Street on Tuesday, with futures for the S&P 500 up 0.5 percent, Dow Jones futures up 0.4 percent and Nasdaq 100 futures up 0.4 percent at 4:10 a.m. EDT.